Advances in the Medical Management of Ovarian Cancer
作者： Timothy John Perren , Faisal Al-Terkait , Sheryl Sim , None
DOI: 10.1007/978-1-4471-2942-4_4
关键词:
摘要: The term ovarian cancer includes a family of diseases with distinct anatomical, morphological, and genetic distinctions. is used to generally encompass tumors that are thought arise from the ovary fallopian tube also primary peritoneal carcinoma. disease carries poor prognosis outlook primarily being dictated by anatomical stage at presentation. A recent analysis Surveillance, Epidemiology, End Results database for US patients presenting epithelial carcinoma between 1995 2007 has demonstrated relative 10-year survival 84 %, 59 23 just 8 % FIGO stages 1, 2, 3, 4, respectively.
springer.com
sci-hub.st 参考文章(122)
Peter Carmeliet, Angiogenesis in life, disease and medicine Nature. ,vol. 438, pp. 932- 936 ,(2005) , 10.1038/NATURE04478
Gordon C. Jayson, Daniel J. Hicklin, Lee M. Ellis, Antiangiogenic therapy—evolving view based on clinical trial results Nature Reviews Clinical Oncology. ,vol. 9, pp. 297- 303 ,(2012) , 10.1038/NRCLINONC.2012.8
Andreas du Bois, Jørn Herrstedt, Anne-Claire Hardy-Bessard, Hans-Helge Müller, Philipp Harter, Gunnar Kristensen, Florence Joly, Jens Huober, Elisabeth Åvall-Lundqvist, Béatrice Weber, Christian Kurzeder, Svetislav Jelic, Eric Pujade-Lauraine, Alexander Burges, Jacobus Pfisterer, Martina Gropp, Anne Staehle, Pauline Wimberger, Christian Jackisch, Jalid Sehouli, Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer Journal of Clinical Oncology. ,vol. 28, pp. 4162- 4169 ,(2010) , 10.1200/JCO.2009.27.4696
Patrick Royston, Mahesh K. B. Parmar, The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Statistics in Medicine. ,vol. 30, pp. 2409- 2421 ,(2011) , 10.1002/SIM.4274
Ursula A. Matulonis, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn Krasner, Corrine Zarwan, Anna Berkenblit, Susana Campos, Neil Horowitz, Stephen A. Cannistra, Hang Lee, Julie Lee, Maria Roche, Margaret Hill, Christin Whalen, Laura Sullivan, Chau Tran, Benjamin D. Humphreys, Richard T. Penson, Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 5601- 5606 ,(2009) , 10.1200/JCO.2009.23.2777
Deborah K. Armstrong, Brian Bundy, Lari Wenzel, Helen Q. Huang, Rebecca Baergen, Shashikant Lele, Larry J. Copeland, Joan L. Walker, Robert A. Burger, Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer The New England Journal of Medicine. ,vol. 354, pp. 34- 43 ,(2006) , 10.1056/NEJMOA052985
Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter G. Harper, David S. Alberts, Michael Friedlander, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth, Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup Journal of Clinical Oncology. ,vol. 27, pp. 1419- 1425 ,(2009) , 10.1200/JCO.2008.19.1684
Viviane Hess, Roger A'Hern, Nazar Nasiri, D. Michael King, Peter R. Blake, Desmond P.J. Barton, John H. Shepherd, T. Ind, J. Bridges, K. Harrington, Stanley B. Kaye, Martin E. Gore, Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment Journal of Clinical Oncology. ,vol. 22, pp. 1040- 1044 ,(2004) , 10.1200/JCO.2004.08.078
J.P. MICHA, B.H. GOLDSTEIN, M.A. RETTENMAIER, M. GENESEN, C. GRAHAM, K. BADER, K.L. LOPEZ, M. NICKLE, J.V. BROWN, A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. International Journal of Gynecological Cancer. ,vol. 17, pp. 771- 776 ,(2007) , 10.1111/J.1525-1438.2007.00886.X
Prognostic factors in early-stage ovarian cancer Ecancermedicalscience. ,vol. 7, pp. 325- 325 ,(2013) , 10.3332/ECANCER.2013.325